Under the terms of the agreement, Biodol will receive an option fee, granting Kyorin the option to in
license BDT272 upon the successful completion of Phase 1 clinical trials. Upon exercise of the option,
Kyorin will be granted a license to develop and commercialize the compound in Japan and selected
additional territories in Asia (excluding China); in turn Biodol will receive upfront payment, milestone
payments tied to the progress of developing and commercializing BDT272, and royalties based on net
sales following its launch.
“We are proud to collaborate with Kyorin, a trusted and well-established partner with deep market
expertise and a proven track record in bringing therapies to patients. This agreement is a key milestone
for Biodol, as we join forces to deliver innovative pain treatments to address significant unmet medical
needs.” said Fabien GRANIER, CEO of BIODOL Therapeutics.
“Our company is focused on pain as one of our key strategic therapeutic areas for research and
development. Through this agreement, we anticipate that this innovative pain treatment candidate
will provide a new treatment option for patients suffering from pain conditions.” said Yutaka Ogihara,
President and CEO of KYORIN Pharmaceutical Co., Ltd.
About Kyorin Pharmaceutical
KYORIN Pharmaceutical Co., Ltd. was founded in 1923. Accelerating its evaluation and acquisition of
in-licensed products and establishing a presence in designated fields, Kyorin aims to contribute
broadly to people’s health by pursuing innovation in drug discovery, in order to strengthen drug
discovery capability and create high-value new drugs that meet medical needs.
About Biodol Therapeutics
Biodol Therapeutics (www.biodol.eu), founded in 2015, specializes in developing first-in-class
compounds for pain treatment. The company has identified the Receptor Tyrosine Kinase (RTK) FLT3
as a key driver in initiating and sustaining neuropathic pain (Nature Communications, 2018). Its
groundbreaking research has also demonstrated that inhibiting FLT3 signaling eliminates opioid
tolerance and hyperalgesia while preserving analgesic efficacy (Nature Communications, 2024). Biodol
Therapeutics is focused on developing allosteric inhibitors of the FLT3 receptor to address various
types of pain. The company holds exclusive rights to a portfolio of four patents and has received
support from BPI France, SATT AxLR, Inserm Transfert, Région Occitanie, the French National Research
Agency, SEMIA Incubator, and the Montpellier Business and Innovation Centre. Biodol was assisted by
MCE Carrel law firm, Alexandra Carrel and Luke Sampson, for this transaction.
For more information, please contact:
Biodol Therapeutics
contact@biodol.eu
